New pricing rules lower access barriers for orphan drugs in France
As recent changes to the price setting of drugs have improved the market access risk environment in France, GlobalData looks…
As recent changes to the price setting of drugs have improved the market access risk environment in France, GlobalData looks…
For its latest high-profile review, the US Institute for Clinical and Economic Review (ICER) concluded that the three COVID-19 pills…
At GlobalData, we track the positive and negative drivers that impact market access at the country level. Through our comprehensive…